Free tool
Rare disease stocks
We cover 4 companies grouped under the Rare disease theme. The median market value in the group is $411.90M. Across the group, the median move over the past trading day is −0.59%. Price change over the past year runs from −32.3% to +26.8% across the middle 80 percent of the group, with a median of −27.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| ABVX.PA | ABIVAX Société Anonyme | 102.30 EUR | −5.63% | −11.04% | +48.91% | Sep 21, 2026 |
| RZLT | Rezolute, Inc. | $5.04 | +2.44% | +132.79% | −30.00% | Sep 16, 2026 |
| CUV.AX | Clinuvel Pharmaceuticals Limited | 9.36 AUD | −2.40% | −26.36% | −24.94% | Aug 27, 2026 |
| 0AB6.L | Hyloris Pharmaceuticals SA | 4.38 EUR | −1.79% | −38.83% | −33.23% | Sep 24, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.